Inspire Fireside Chat with Dr. Nabanita Nawar
Join us for a fireside chat, featuring Dr. Nabanita Nawar, CEO and Co-founder at HDAX Therapeutics
HDAX Therapeutics is a biotechnology company pioneering a novel approach to target HDAC6 to address critical unmet medical needs in cardiometabolic, inflammatory, and select neurological diseases. Their innovative 2-site binding mechanism has the potential to deliver best-in-class HDAC6-targeting therapeutics and tackles major limitations of first generation HDAC inhibitors, such as weak binding, poor selectivity, suboptimal pharmacokinetics, and off-target toxicities. HDAX closed an oversubscribed >$5M CAD seed financing round in Q4 2024 to nominate a development candidate and advance its pipeline programs.
WHEN: Thursday, April 24, 2025 (12 – 1 PM ET)
WHERE: Zoom; Register today!
ECHO Discovery is funded and organized by the Translational Biology & Engineering Program and TRANSFORM HF, at the University of Toronto and the Ted Rogers Centre for Heart Research. For more information, visit: https://tedrogersresearch.ca/echo-discovery/
